Teva announced the launch of Fluvastatin Sodium Extended-Release Tablets, the generic version of Novartis’ Lescol XL

Lescol XL is indicated as adjunct to diet in primary hypercholesterolemia and mixed dyslipidemia (Types IIa and IIb) to reduce elevated total-C, LDL-C, TG, and apo B, and to increase HDL-C when response to nondrug therapy is inadequate; adjunct to diet to reduce total-C, LDL-C and apo B in patients 10–16 years of age (≥1 year post-menarche) with heterozygous familial hypercholesterolemia if LDL-C remains ≥190mg/dL, or if LDL-C remains ≥160mg/dL with either family history of premature cardiovascular disease (CVD) or if patient has at least 2 other CVD risk factors; and in patients with coronary heart disease to slow the progression of coronary atherosclerosis to lower total-C and LDL-C, and to reduce the risk of undergoing coronary revascularization procedures. 

Related Articles

Fluvastatin sodium is a competitive inhibitor of HMG-CoA reductase. The inhibition of cholesterol biosynthesis reduces the cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors and thereby increases the uptake of LDL particles. This results in a reduction of the plasma cholesterol concentration. 

Fluvastatin Sodium Extended-Release Tablets are available in a 80mg strength in 30- and 100-count bottles. 

For more information call (888) 838-2872 or visit